2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Vaccines, Bispecific Antibody Therapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Measurable Residual Disease, ALL, B Cell Lymphoma, T Cell Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

5045 Oral chemotherapy nonadherence and event-free survival in pediatric acute lymphoblastic leukemia: A report from the DFCI ALL Consortium protocol 16-001

Justine M. Kahn, MD, MS, Hital Patel, BS2, Julia Keating, M.S.3, Yael Flamand, MS4, Kathryn McHenry, MD5, Victoria B. Koch, BS6, Song Yao, MD, PhD7, Nobuko Hijiya, MD8, Melissa A. Burns, MD9, Peter D. Cole, MD10, Lisa M. Gennarini, M.11, Bruno Michon, MD12, Andrew E. Place, MD, PhD13, Thai Hoa Tran, MD14, Jennifer J.G. Welch, MD15, Elizabeth Bouchard, PhD16, Kira Bona, MD, MPH17, Lewis B. Silverman, MD18, Kara M. Kelly, MD19
1 Columbia University Irving Medical Center, New York, NY, United States
2 Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States
3 Dana-Farber Cancer Institute/Boston Children’s Hospital, Harvard Medical School, Boston, MA, United States
4 Dana-Farber Cancer Institute/Boston Children’s Hospital, Harvard Medical School, Boston, MA, United States
5 University of California, San Fransisco, San Francisco, CA, United States
6 Dana-Farber Cancer Institute/Boston Children’s Hospital, Harvard Medical School, Boston, MA, United States
7 Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States
8 Columbia University Irving Medical Center, New York, NY, United States
9 Dana-Farber Cancer Institute/Boston Children’s Hospital, Harvard Medical School, Boston, MA, United States
10 Rutgers Cancer Institute, New Brunswick, NJ, United States
11 Children's Hospital of Montefiore, Bronx, NY, United States
12 Centre Hospitalier Universitaire de Quebec, Saint-Foy, Quebec, Canada
13 Dana-Farber Cancer Institute/Boston Children’s Hospital, Harvard Medical School, Boston, MA, United States
14 Charles-Bruneau Cancer Center – CHU Sainte-Justine, Montréal, Quebec, Canada
15 Hasbro Children’s Brown University Health/Brown University, Providence, Rhode Island, United States
16 Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States
17 Dana-Farber Cancer Institute/Boston Children’s Hospital, Harvard Medical School, Boston, MA, United States
18 Columbia University Irving Medical Center, New York, NY, United States
19 Roswell Park Comprehensive Cancer Center, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, United States

Background: Nonadherence to oral 6-mercaptopurine (6MP) during maintenance is associated with relapse among patients treated for acute lymphoblastic leukemia (ALL) on Children’s Oncology Group (COG) trials. Whether nonadherence to dexamethasone (DEX) is associated with relapse is not known, nor is the impact of nonadherence among children treated on non-COG trials. The Dana-Farber Cancer Institute (DFCI) ALL Consortium protocols use repeating 3-week cycles of oral 6MP and DEX during post-induction therapy, with a higher-touch model of patient-provider clinic visits compared to COG. The most recent DFCI Consortium trial 16-001 included an embedded correlative study of 6MP and DEX adherence measured with Medication Event Monitoring System (MEMS) Caps. We evaluated whether nonadherence to 6MP and/or DEX was associated with event-free survival (EFS) on DFCI 16-001.

Methods: DFCI ALL Consortium Protocol 16-001 (NCT03020030) was a phase 3 randomized clinical trial enrolling patients aged 1–21 yrs with newly diagnosed ALL at 8 United States and Canadian sites from 2017–2022. Treatment included a 30-week Consolidation II phase followed by a 70-week Continuation (maintenance) phase. During both phases, caregivers administered 6MP for 14 consecutive days and twice-daily DEX for 5 consecutive days, every 3 weeks. For the correlative adherence study, eligible participants had an English, Spanish-, or French-speaking caregiver, had achieved complete remission and could receive medications using electronic monitoring bottles. MEMS monitoring of liquid and/or pill formulations occurred over 3 consecutive cycles during both Consolidation II (year 1) and Continuation (year 2). Adherence was calculated as the percentage of prescribed medication days with bottle openings, excluding days when therapy was held or interrupted for hospitalization. For the present analysis, adherence levels were categorized using prespecified 90% and 95% thresholds. Recursive partitioning identified data-driven thresholds of 91% and 96% for sensitivity analyses. EFS, defined as time from registration to relapse, death, second malignancy, was estimated using Kaplan-Meier methods and compared by log-rank tests. Cox proportional hazards models estimated hazard ratios (HR) and 95% confidence intervals (CIs).

Results: Among 429 eligible families, 219 participated and were included in this analysis. The cohort was 68% non-Hispanic White, 17% Hispanic, 9% non-Hispanic Other race/ethnicity, and 7% non-Hispanic Black. Median age of pts was 5.2 yrs; 88% (N=192) had B-cell ALL, 12% (N=27) T-ALL. At median follow-up of 5.6 years (5.1–6.1), 19 patients experienced an event, with 5-yr EFS rate 91% (95%CI, 87%–95%).

For 6MP, 19% and 32% of pts were non-adherent at a 90% and 95% threshold, respectively. For DEX, the non-adherent rates were 8% and 15%, respectively. 5-year EFS did not differ significantly by 6MP nonadherence at either the 90% (5-year EFS 91% in adherent vs 90% in nonadherent group; p=0.8) or 95% threshold (91% vs 89%; p=0.7), nor by DEX nonadherence at the 90% (86% vs 92%; p=0.6) or 95% threshold (90% vs 92%; p=0.4). Results from sensitivity analyses (with the thresholds of 91% and 96%) were also not significant. In univariable Cox models, nonadherence was not significantly associated with EFS for 6MP at ≥90% (HR, 1.21; 95%CI, 0.35–4.14) or ≥95% (HR, 1.26; 95%CI, 0.46–3.51), nor DEX at ≥90% (HR, 0.66; 95%CI, 0.15–2.88) or ≥95% (HR, 0.65; 95%CI, 0.21–1.97). The associations remained non-significant in multivariable models adjusting for demographics and disease risk group.

Conclusions: In this prospective, MEMS-monitored cohort, rates of oral chemotherapy nonadherence were high, but neither 6MP nor DEX nonadherence was associated with EFS. Findings suggest that with this treatment backbone, factors other than 6MP or DEX adherence during post-induction therapy may have greater impact on subsequent relapse risk. However, given the small number of observed events, power was limited to detect whether nonadherence had a small or moderate (but clinically meaningful) effect on EFS. As ALL treatment regimens evolve and immunotherapy replaces more intensive cytotoxic chemotherapy agents, the role of oral chemotherapy may change. Future studies with electronic monitoring may help to better define the contribution of oral chemotherapy to outcomes with newer regimens and concurrently, support for families to improve overall treatment adherence will remain essential.

Justine M. Kahn, MD, MS: No relevant conflicts of interest to declare.